Caxton Associates (New York)’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Caxton Associates (New York)’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-85,544	Closed	-$1.15M	–	692
2023 Q1	$1.15M	Buy	85,544 +8,880	+12%	+$154K	0.17%	121
2022 Q4	$948K	Sell	76,664 -5,694	-7%	-$80.6K	0.06%	120
2022 Q3	$1.15M	Buy	82,358 +39,705	+93%	+$639K	0.15%	85
2022 Q2	$589K	Hold	42,653	–	–	0.06%	233
2022 Q1	$694K	Sell	42,653 -13,420	-24%	-$210K	0.06%	168
2021 Q4	$913K	Buy	+56,073	New	+$945K	0.09%	129

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Caxton Associates (New York)'s ICPT Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2023, closing a stake of 85,544 shares — an estimated $1.15M sold.

Caxton Associates (New York) first reported a position in ICPT in Q4 2021 and held it in 6 quarters. The position peaked at $1.15M in Q3 2022. 126 funds tracked by Wall St. Rank hold ICPT as of Q2 2023.

Caxton Associates (New York) reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Caxton Associates (New York) sold 85,544 Intercept Pharmaceuticals, Inc. shares in Q2 2023, an estimated $1.15M.
Caxton Associates (New York) first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2021 and held it in 6 quarters.
Caxton Associates (New York)'s Intercept Pharmaceuticals, Inc. position peaked at $1.15M in Q3 2022.
126 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.